Ten stocks kicked off the trading week with strong gains, bucking a lackluster performance on the broader market, thanks to a flurry of positive industry news that spilled over to their stocks. Of the 10 in the list, five notably hit new record highs.
Among Wall Street’s three major indices, only the Dow Jones finished in the green, up 0.29 percent. The Nasdaq and the S&P 500, on the other hand, declined by 1.32 percent and 0.37 percent, respectively.
In this article, we spotlight the 10 top-performing stocks on Monday and break down the reasons behind their gains.
Our list exclusively considered the stocks with a market capitalization of $2 billion and 5 million shares in trading volume.
The New York Stock Exchange building. Photo by Дмитрий Трепольский on Pexels
10. Innio NV (NASDAQ:INIO)
Innio saw its share prices climb to a fresh high on Monday, as investors positioned their portfolios amid the rosy prospects for its business, thanks to the rapidly growing artificial intelligence industry.
Innio NV (NASDAQ:INIO)—which only joined the roster of publicly listed companies on June 8—has already seen its stock price climb to as much as 27 percent since its IPO, amid a combination of strong demand for energy from the power-hungry AI data centers, alongside optimism from market analysts.
Mad Money host and former hedge fund manager Jim Cramer, for his part, recommended buying Innio NV shares, saying that the company is similarly a “hostage to AI.”
“Until we see a slowdown in the great data center buildout, and I don’t think we’re going to, I am not fretting it. Here’s the bottom line: I think Innio is worth owning here. And while I prefer you wait for a pullback to pull the trigger, it wouldn’t be crazy to put on a small position, at least right here, right now,” Cramer said.
Innio NV joined the stock market without raising any funds, with 90 million of its shares sold during the IPO fully raised by its existing shareholders for a total of $2.43 billion.
Backed by Advent and ADIA, it is a global distributed energy solutions provider that commits to delivering reliable, flexible, transient, decentralized, modular, and efficient power through the design, manufacture, and service of high-performance power systems under its Jenbacher and Waukesha brands.
The company delivers power for applications including data centers, microgrids, grid stabilization, industrial energy, and gas compression.
9. T1 Energy Inc. (NYSE:TE)
T1 Energy saw its share prices jump by 11.23 percent on Monday to close at $10.40 apiece as investors loaded up on its shares following its official inclusion in the S&P Semiconductors Select Industry Index.
On the same day, June 22, the S&P Dow Jones Indices named T1 Energy Inc. (NYSE:TE) as one of the companies added to the S&P Semiconductors Select Industry, sparking significant buying demand among investors.
Companies being added to or removed from benchmark indices typically see a significant movement in their share prices as exchange-traded funds tracking them would need to rebalance their portfolios to mirror their composition.
This also provided higher exposure for its stock across global retail and institutional investors.
In other news, T1 Energy Inc. recently earned a market perform rating from investment firm Bernstein, alongside a $9 price target for its stock. The figure was 13 percent lower than its latest closing price.
Bernstein said that the coverage reflected its position on T1 Energy Inc.’s outcomes tied to its second manufacturing facility buildout, the contracting backdrop, and an unresolved patent dispute with First Solar Inc.
8. Credo Technology Group Holding Ltd. (NASDAQ:CRDO)
Credo Technology rallied to a fresh all-time high on Monday, as investors took heart from an investment firm’s bullish coverage for its stock amid further rosy prospects from AI.
In intra-day trading, the stock jumped to its highest price of $308.67 before paring gains to end the session just up by 11.29 percent at $302.52 apiece.
In a market note during the day, BNP Paribas said that it expects Credo Technology Group Holding Ltd. (NASDAQ:CRDO) to continue benefitting from the artificial intelligence buildout amid its copper and optical interconnects.
“We continue to view Credo as a key beneficiary of hyperscalers adopting innovations in copper and optical interconnects for both scale-out and scale-up backend networks, as well as frontend network deployments driven by agentic AI,” BNP said.
“Indeed, we believe [active electrical cables], ZF optical transceivers, silicon photonics, Active LED Cables, and OmniConnect gearboxes expand Credo’s [total addressable market] to over $10 billion, or 3x from Credo’s opportunity just 18 months ago,” it noted.
However, BNP issued a price target of $275 on shares of Credo Technology Group Holding Ltd., lower by 9 percent than its closing price on Monday.
It said that the company is increasingly diversifying its customer base, with 3-4 10 percent hyperscale customers expected in full-year 2027.
“We also expect Neoclouds to approach 20 percent of sales over time. Credo initiated that they are involved with 5 of 6 hyperscalers, which we believe are Amazon, Meta, Microsoft, xAI, and Oracle.”
7. Precigen Inc. (NASDAQ:PGEN)
Precigen rallied for a second day on Monday, surging 11.62 percent to end at $5.38 apiece, as investors loaded portfolios ahead of the end of the second quarter, with optimism for the period boosted by the orphan drug exclusivity of its therapy for recurrent respiratory papillomatosis (RRP).
Late last month, Precigen Inc. (NASDAQ:PGEN) secured a six-year approval from the Food and Drug Administration (FDA) to exclusively treat RRP in the US through its therapy, Papzimeos.
Orphan drug exclusivity is granted to certain drugs and biologics approved for rare diseases or conditions that affect fewer than 200,000 people in the United States, and will benefit Precigen Inc. until August 14, 2032.
“This regulatory exclusivity, together with Precigen’s patent portfolio covering Papzimeos and its therapeutic use, enhances the product’s value by strengthening market protection and long-term revenue potential, which in turn supports continued innovation for rare diseases,” Precigen Inc. President and CEO Helen Sabzevari earlier said.
6. Viavi Solutions Inc. (NASDAQ:VIAV)
Viavi Solutions rebounded by 12.23 percent on Monday to close at $52.94 apiece, as investor sentiment was boosted by its official inclusion in a benchmark index.
Earlier this month, the S&P Dow Jones Indices announced the inclusion of five companies in the S&P MidCap 400, including Viavi Solutions Inc. (NASDAQ:VIAV). Other companies include Sanmina, Semtech, Coeur Mining, and Roku. The recomposition took effect on the same day, June 22.
Meanwhile, the S&P Dow Jones Indices dropped Flex, BellRing Brands, Coty, Concentrix, and Blackbaud from the same group.
Companies added to or removed from benchmark indices typically see a significant movement in their share prices as exchange-traded funds tracking the indices would need to rebalance their portfolios to mirror their composition.
In other developments, the rally can also be partly attributed to Viavi Solutions Inc.’s announcement last week that its Xgig platform for PCI Express 6.0 specification testing has achieved Gold Suite acceptance from PCI-SIG.
The recognition enables the platform to be used for PCIe 6.0 link and transaction protocol compliance testing at PCI-SIG compliance workshops worldwide.
“Designed to support AI workloads and other high-performance computing applications, PCIe 6.0 specification delivers faster, more dependable data transfer, driving greater overall efficiency,” Viavi Solutions Inc. SVP and General Manager for Lab Production Tom Fawcett said.
“Compliance testing remains a cornerstone of PCI-SIG’s standards development, and we look forward to continuing to support its members in upcoming compliance workshops.”
5. Biohaven Ltd. (NYSE:BHVN)
Biohaven saw its share prices climb by 14.22 percent on Monday to finish at $15.50 apiece, as investors resumed buying positions ahead of the initiation of two clinical studies by the end of the month.
Based on its key milestone calendar, Biohaven Ltd. (NYSE:BHVN) is set to initiate clinical studies for its BHV-1510 for advanced or metastatic epithelial tumors, as well as the BHV-1530 for urothelial cancer and other tumors, by the end of the month.
It is also planning to begin pivotal studies for BHV-1400 for the treatment of IgAN, or Berger disease, as well as BHV-1300 for Graves’ disease, in the middle of the year.
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology.
In the first quarter of the year, it was able to slash its net losses by 41 percent to $130.5 million from $221.7 million in the same period last year. It has yet to generate revenues as of the period.
4. United Microelectronics Corp. (NYSE:UMC)
United Microelectronics saw its share prices jump to a new all-time high, as investors loaded portfolios following reports that it is collaborating with Intel Corp. for the production of semiconductors.
In intra-day trading, the stock climbed to its highest price of $28.27 before paring gains to finish the session just up by 14.20 percent at $27.50 apiece.
An unverified report on the same day said that United Microelectronics Corp. (NYSE:UMC) is partnering with Intel Corp. anew for the development of advanced manufacturing process technologies.
The report added that the partnership would primarily focus on chips using 12nm and 3nm process nodes, with production expected to take place at Intel’s facility in Arizona.
United Microelectronics Corp., however, refused to issue a statement in relation to the buzz, saying that it “does not comment on unverified reports.”
If proven, the deal would mark a deepened collaboration between United Microelectronics Corp. and Intel, having already joined forces in 2024 for the development of a 12nm process platform.
Under their previous agreement, the two firms engaged in the development of a 12-nanometer semiconductor process platform to address high-growth markets such as mobile, communication infrastructure, and networking.
3. Super Micro Computer Inc. (NASDAQ:SMCI)
Super Micro rallied for a second day on Monday, jumping 15.66 percent to finish at $35.46 apiece, as investors loaded portfolios following the launch of a new blueprint for the development of next-generation AI and supercomputing data centers.
At the ongoing ISC 2026 conference in Hamburg, Germany, Super Micro Computer Inc. (NASDAQ:SMCI) unveiled its new blueprint, powered by Nvidia Corp.’s Vera Rubin NVL4 platform, and is designed for high-performance computing systems.
It said that the blueprint is based on Supermicro’s DCBBS, which provides the necessary compute, networking, advanced liquid cooling, power distribution, and site infrastructure, delivered by a team of Supermicro DCBBS experts to accelerate time-to-online for research institutions and supercomputing centers.
“Scientific discovery has always been driven by the tools available to researchers, and AI has become an essential part of the research process,” Super Micro Computer Inc. President and CEO Charles Liang said.
“The institutions that accelerate infrastructure deployment will lead the next generation of breakthroughs. With our DCBBS Blueprints for NVIDIA Vera Rubin NVL4, research organizations can confidently deploy HPC and AI infrastructure at any scale, knowing that it is backed by Supermicro’s proven experience building some of the world’s largest liquid-cooled clusters,” he noted.
2. Apogee Therapeutics Inc. (NASDAQ:APGE)
Apogee Therapeutics soared to a fresh all-time high on Monday, as investors gobbled up shares following announcements that it is set to be acquired by pharmaceutical giant AbbVie Inc. at a 49 percent premium.
In a joint statement on the same day, the two firms said that they have officially inked a definitive agreement for their planned merger for a total of $10.9 billion.
Under the terms of the agreement, AbbVie will acquire all shares of Apogee Therapeutics Inc. (NASDAQ:APGE) at a price of $135.11 apiece, or a 49.5 percent premium over its closing price of $90.38 on Friday, or prior to the announcement.
Following the news, Apogee Therapeutics Inc. climbed to its highest price of $133 before trimming gains to finish the session up by 46.66 percent at $132.55 apiece.
AbbVie said that the acquisition forms part of its efforts to strengthen its portfolio in immunology, given Apogee Therapeutics Inc.’s diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory, and other related inflammatory and immunological diseases.
Subject to regulatory approvals, including shareholders, the transaction is expected to be completed in the third quarter of the year.
1. Definium Therapeutics Inc. (NASDAQ:DFTX)
Definium Therapeutics saw its share prices jump to a nearly five-year high on Monday, as investors positioned their portfolios after reporting strong results from the late-stage clinical trial of its therapy candidate for major depressive disorders (MDD).
In intra-day trading, the stock climbed to a record high of $39.16 before trimming gains to end the session just up by 49.80 percent at $36.67 apiece.
In an updated report during the day, Definium Therapeutics Inc. (NASDAQ:DFTX) said that the Least Squares Mean—a statistical method used to calculate the average improvement in depression symptom scores—stood at -13.3 for patients in the DT120 group, as compared with the -5.2 for patients in the placebo group, at week 6.
DT120 was able to achieve all key primary and secondary endpoints, demonstrating statistically significant and clinically meaningful improvement from baseline.
Definium Therapeutics Inc. was also generally well-tolerated, with 99 percent of adverse effects only mild to moderate in severity, and were only transient and predominantly occurring on the day of dosing.
Importantly, no new safety signals were identified, including no increase in suicidal ideation or behavior. Discontinuations were also low and comparable between treatment groups.
“The Emerge topline results represent unprecedented and highly differentiated efficacy, demonstrating that a single dose of DT120 ODT can deliver rapid, robust, and durable relief in MDD,” Definium Therapeutics Inc. CEO Rob Barrow said.
“Emerge (the study) marks a major milestone in our development program and strengthens our confidence in DT120 as a potential best-in-class treatment for mental health disorders. These findings could support a fundamentally new approach to treating MDD for patients and providers who continue to face the limitations of existing treatment options. We are deeply grateful to the patients and investigators who participated in this trial,” he noted.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
